For most of sleep apnea’s history, the answer was no. But that changed in late 2024 when the FDA approved the first medication for obstructive sleep apnea (OSA), and several other drugs are in development. The options are still limited compared to CPAP, and no pill yet replaces it entirely, but pharmaceutical treatment is no longer just a future possibility.
The First FDA-Approved Medication for OSA
The FDA approved tirzepatide (brand name Zepbound) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity. This is the same drug already used for weight loss and type 2 diabetes. It works by mimicking gut hormones that reduce appetite and food intake, and the improvement in sleep apnea appears to come directly from the resulting weight loss.
The clinical data is striking. In two 52-week trials published in the New England Journal of Medicine, participants taking tirzepatide experienced a reduction of about 25 to 29 breathing interruptions per hour of sleep, compared to roughly 5 per hour with placebo. That’s a meaningful difference. Greater proportions of people on the drug achieved either full remission or mild sleep apnea with symptoms resolved, compared to those on placebo.
There’s an important catch: this approval is specifically for people who have both OSA and obesity. If your sleep apnea isn’t related to excess weight, or if your BMI doesn’t qualify, this medication isn’t indicated for you. It also requires a reduced-calorie diet and increased physical activity alongside the injections (tirzepatide is a weekly injection, not a pill). And it takes time. The trial results were measured at 52 weeks, so this isn’t a quick fix.
Pills That Help You Stay Awake, Not Stop Apnea
Before tirzepatide, the only medications prescribed in the context of sleep apnea didn’t treat the apnea itself. They treated one of its most debilitating symptoms: excessive daytime sleepiness. Solriamfetol (brand name Sunosi) is approved to improve wakefulness in adults with OSA who still feel excessively sleepy despite using CPAP or other treatments. It’s taken once daily, starting at a low dose and typically going up to 150 mg.
These wake-promoting medications can make a real difference in daily functioning, but they do nothing to stop your airway from collapsing at night. Your breathing events continue at the same rate. You still need CPAP or another mechanical treatment to address the underlying problem. Think of them as add-on therapy for the leftover sleepiness that CPAP doesn’t always fully resolve.
Common side effects of these stimulant-type medications include headaches, nausea, anxiety, trouble sleeping (ironic, given the condition), and elevated blood pressure.
Off-Label Options: What Doctors Sometimes Try
Some medications are used off-label for sleep apnea, meaning they’re approved for other conditions but have shown some effect on breathing during sleep. Acetazolamide, a drug originally developed for other purposes, has been studied in both obstructive and central sleep apnea. A meta-analysis in CHEST Journal found it reduced breathing interruptions by about 38%, corresponding to roughly 14 fewer events per hour in people who averaged about 37 events per hour at baseline. Some individual studies showed even larger reductions, with a median decrease close to 50%.
That sounds promising, but acetazolamide comes with a long list of potential side effects: taste changes, fatigue, abdominal pain, diarrhea, nausea, tingling sensations, frequent urination, and kidney stones with prolonged use. It’s not a comfortable daily medication for many people, and it’s not FDA-approved for this purpose.
Drugs in the Pipeline
Several pharmaceutical companies are developing combination pills that target the muscles controlling airway tone during sleep. The general idea is to combine one drug that activates airway-opening muscles with another that prevents them from relaxing too much. One such combination pairs a norepinephrine reuptake inhibitor with an antimuscarinic agent. Early-phase trials have shown enough promise to move into larger studies, but no results from late-stage trials are publicly available yet.
If these drugs pan out, they would represent the first true pill for sleep apnea: something you swallow before bed that directly prevents airway collapse. But they haven’t crossed the finish line, and many promising drug candidates fail in later trials.
How Pills Compare to CPAP
CPAP remains the gold standard for a reason. It reduces breathing interruptions to a median of about 2.5 events per hour, which is essentially normal. No medication comes close to that level of control. Even tirzepatide, with its impressive 25-to-29-event reduction, still leaves many patients with residual apnea, especially those who started with severe disease.
The case for medication usually centers on adherence. CPAP works brilliantly when people use it, but not everyone does. Overall adherence sits around 78%, with people who have mild sleep apnea being the least likely to stick with it (about 55% adherence) and those with severe apnea the most likely (89%). Among those who do use their machines, the average is about 6 hours per night, which leaves part of the sleep period uncovered.
A pill you take once a day has an obvious compliance advantage. If future medications can get even close to CPAP’s effectiveness at eliminating breathing events, the adherence benefit alone could make them a better option for certain patients. We’re not there yet, but the gap is narrowing.
What This Means for You Right Now
If you have sleep apnea and obesity, tirzepatide is a real option worth discussing, though it requires weekly injections rather than a daily pill, and the full effect takes months to develop. If you’re already using CPAP but struggling with daytime sleepiness, wake-promoting agents like solriamfetol can help with alertness. If you can’t tolerate CPAP at all, your doctor may consider off-label options like acetazolamide depending on the type and severity of your apnea.
For the person hoping to swap their CPAP machine for a simple bedtime pill, the honest answer is: not yet, but probably within the next several years. The first approval has opened the door, and multiple drug candidates are in active development targeting the mechanical problem of airway collapse directly.